Dr Reddy's: R&D Investments paying off - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr Reddy's: R&D Investments paying off

Aug 5, 1999

Dr Reddy's will be launching two new anti cancer drugs, irinotecan and topotecan, in the last quarter of the current financial year. The company has also developed a new molecule for chemotherapy, which is expected to get clearance for clinical trials shortly. Dr Reddy's is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has developed from being a purely bulk drug based company to a formulation-based company. The company is one of the leading spenders on R&D in India.

Dr Reddy's has been aggressively investing in research and development (5% of sales in FY99) in order to stay competitive after the product patents are recognised in India. The company has achieved some measure of success in the anti diabetes segment. The molecules developed have been licensed to Novo Nordisk, which pays Dr Reddy's milestone payments as and how the clinical trials progress.

While the two cancer drugs are already patented in the international markets, the new molecule for chemotherapy is likely to undergo Phase 1 clinical trials once the application is approved. This will make Dr Reddy's the second Indian company, after Ranbaxy, to have a product under Phase 1 trials in the country.

The company has priced the new anti cancer product Docetere at Rs 9,000 per vial, which is a quarter of the price at which patent holders Rhone Poulenc sells it.

The Indian companies still lack funds to carry on large scale R&D and go through the entire process of developing a product, testing it and finally launching it. Until that point is reached, Indian companies will have to keep licensing out most of the promising molecules to international firms in return for fees and royalties.

Market View:
Analysts are increasingly getting convinced of the seriousness of the R&D efforts of the company. They are recommending a 'BUY' as they expect the R&D efforts to yield returns for the company in the future.

Equitymaster requests your view! Post a comment on "Dr Reddy's: R&D Investments paying off". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 20, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 8-QTR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS